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Abstract The treatment of metastasized renal cell carci­
noma (RCC) still represents a formidable challenge, 
despite the development of small molecule, tyrosine kinase 
inhibitors (TKI) that have made a major impact on the 
disease. Although the percentage of patients achieving a 
partial response or stabilization of disease has been 
impressive, these effects are mostly non-durable. Addi­
tionally, drug-related side effects can be quite severe. 
Alternative treatment modalities might be monoclonal 
antibodies (mAbs). mAbs against RCC-associated antigens 
have been developed and have shown promise. Addition­
ally, current efforts focus on Bevacizumab that recognizes 
vascular endothelial growth factor (VEGF). VEGF over­
expression in RCC provides the opportunity to inhibit this 
proangiogenic pathway. Also with Bevacizumab, promis­
ing results have been obtained, particularly in combination 
with other treatment modalities. It is likely that mAbs, 
either as single agents or in combination with other agents,
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may become useful additions to the armamentarium to 
diagnose and treat RCC.
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Introduction
The hypothesis by Ehrlich in early 1900s that malignant 
cells express unique structures that can be used to guide 
cytotoxic therapy to tumors [1] followed by the develop­
ment of the hybridoma technique by Kohler and Milstein 
almost 70 years later [2] has led to the development of anti­
cancer reagents with unique characteristics. One of the 
most distinguishing factors is the possibility to select 
monoclonal antibodies (mAbs) recognizing target mole­
cules with very restricted expression in normal tissues. To 
date, tumor-specific antigens (antigens expressed on all 
tumor cells of a particular tumor type not expressed by 
normal cells) have not been identified. The members of the 
so-called cancer-testis family do exhibit highly tissue- 
restricted expression, but are considered promising target 
molecules for cancer vaccines, less for antibody therapy, 
particularly in view of the extreme intra- and inter-tumor 
heterogeneity [3].
Similar to other malignancies, monoclonal antibodies 
(mAbs) targeting renal cell carcinoma (RCC) associated 
molecules were developed without understanding the 
molecular events underlying RCC [4- 8]. The increased 
understanding of molecular events important in the carci­
nogenesis of RCC led to the recognition that these 
aberrations can be used to target RCC. Specifically, aber­
rant von Hippel-Lindau (VHL) gene expression has been 
identified as a general event in clear cell RCC (ccRCC) [9],
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which represents 80-85% of localized cases and 90-95% 
of metastatic RCC (mRCC). The loss of a functional VHL 
gene product leads to accumulation of the transcription 
factor HIF-1a that is an obligatory element for the tran­
scription of several genes. This includes vascular 
endothelial growth factor (VEGF) and carbonic anhydrase 
9 (CA9), targets for which most clinical experience with 
mAbs in RCC has been generated (Bevacizumab and 
G250, respectively).
The rationale and effects of Bevacizumab and G250- 
directed therapy are fundamentally different: Bevacizumab 
treatment leads to VEGF-depletion and consequently to 
diminished neovascularization followed by tumor cell 
death, mainly due to loss of vascularization. In contrast, 
G250 treatment targets the cell surface of RCC cells where 
it must exert toxic effects. Both approaches have advan­
tages and disadvantages. Bevacizumab treatment has the 
advantage that VEGF depletion can be achieved in the 
circulation, and homing to all tumor vessels is not neces­
sary. However, other regulatory pathways can also lead to 
neovascularization and small, non-vascularized tumor loci 
will not be affected. G250 treatment has the advantage that 
RCC cells can be targeted, irrespective of tumor size. 
However, in view of the generally poor perfusion rate and 
high interstitial fluid pressure in RCC, deep penetration of 
tumors may be difficult. Also, since G250-binding alone 
does not confer a lytic signal to RCC cells, tumor cell kill 
requires effector cells or coupling of G250 to toxic agents.
Bevacizumab
Bevacizumab is a humanized mAb against VEGF that 
binds and neutralizes all of the major isoforms of VEGF
[10]. This prevents VEGF from interacting with its recep­
tors and activation of downstream signaling pathways. This 
mode of action is thought to lead to regression of existing 
microvasculature, normalization of mature vasculature, and 
inhibition of the production of new vasculature [11]. 
Whether all these effects are true for RCC is unclear at the 
moment.
Significant protein dose levels are needed to maintain 
sufficiently high Bevacizumab levels to trap VEFG, the 
target of Bevacizumab. The first Bevacizumab trial in 
metastatic RCC (mRCC) patients addressed whether Bev- 
acizumab treatment could lengthen the time to progression 
of disease and the response rate [12]. Survival was a sec­
ondary end point. In this randomized phase II trial, 116 
patients with metastatic, refractory clear cell RCC were 
randomized to placebo, low-dose (3 mg/kg) Bevacizumab, 
or high-dose (10 mg/kg) Bevacizumab given intravenously 
every 2 weeks. All patients had prior disease progression 
while on systemic treatment; the vast majority had received
prior interleukine-2. Patients with disease progression on 
placebo crossed over to receive low-dose Bevacizumab. 
Bevacizumab treatment resulted in a significant prolonga­
tion of the time to progression of disease in the high-dose 
antibody group (4.8 months as compared with 2.5 months). 
Possibly, the low-protein dose was inadequate to suffi­
ciently deplete circulating VEGF levels in-between 
injections, explaining the poor outcome in this group. The 
study was inadequately powered to show a significant 
difference in overall survival between groups. Based on 
this encouraging result, Bevacizumab has been combined 
with other treatment modalities to augment the therapeutic 
index.
Bevacizumab in combination
The AVOREN trial investigated the effects of standard 
therapy of interferon alfa-2a plus placebo or interferon 
alfa-2a plus Bevacizumab, administered every 2 weeks at 
a dose of 10 mg/kg [13]. In this randomized, double blind 
phase III trial, 649 patients with first-line mRCC were 
enrolled. The primary analysis endpoint was assessment 
of improvement in progression-free survival (PFS), 
defined as the length of time the tumor did not grow or 
patient death did not occur. Other endpoints of the study 
included overall survival, time to progression, time to 
treatment failure, overall response rate, and safety profile. 
The addition of Bevacizumab to IFN-a2a significantly 
increased PFS (10.2 vs. 5.4 months) and objective tumor 
response rate (30.6 vs. 12.4%; P < 0.0001). Additionally, 
the combination treatment showed a trend toward 
improved overall survival (P =  0.0670), which leads to 
the conclusion that the combination of Bevacizumab with 
IFN-a2a is superior to either of the single treatment 
regimens in mRCC. The working mechanism explaining 
the superiority of this combination treatment has not been 
defined yet, but most likely the superiority is the net 
effect of the reduction of the immunosuppressive effects 
due to decreased VEGF levels combined with the 
immunomodulatory effects of IFN.
Considering that the epidermal growth factor receptor 
(EGFR) is also overexpressed in RCC, a multicenter, phase
II study evaluated the addition of erlotinib (Tarceva), an 
EGFR inhibitor, to Bevacizumab in metastatic RCC 
patients [14]. Treatment consisted of 10 mg/kg Bev- 
acizumab given intravenously every 2 weeks and 150 mg 
erlotinib given orally each day. With 15 (25%) patients 
showing objective responses, and an additional 36 patients 
(61%) with stable disease after 8 weeks of treatment, a 
randomized phase II trial was performed evaluating Bev- 
acizumab +  placebo versus Bevacizumab +  erlotinib. 
Disappointingly, identical response rates and PFS rates for
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the two arms were observed [15], and it is doubtful that 
EGFR-targeting is of any benefit.
The effect of Bevacizumab and low-dose interleukine-2 
(IL-2) in mRCC was evaluated in a phase II trial in pre­
viously untreated, good and intermediate risk, mRCC 
patients. Patients received 8-week cycles of IL-2 
(250,000 U/kg per day s.c. Day 1-5 during week 1 and 
125,000 U/kg per day s.c. Day 1-5 during weeks 2-6, 
followed by a 2 week break), and Bevacizumab 10 mg/kg 
was administered i.v. every 2 weeks starting on day-14. 
With 16 of the planned 35 patients enrolled, and 11 
evaluable patients for response, 1 partial response (PR) and 
3 stable disease (SD) lasting >3 months were observed 
[16]. All patients with SD demonstrated some degree of 
tumor shrinkage. Similar to the working mechanism of the 
Bevacizumab/IFN combination, the anti-tumor effects are 
possibly the result of the reduction of the immunosup­
pressive effects due to decreased VEGF levels combined 
with the general immune activating effects of IL-2. Inter­
estingly, treated patients demonstrated an increase in the 
number of regulatory T cells without effect on DC acti­
vation. Larger, randomized studies will be necessary to 
address the value of this combination treatment.
In a phase I trial, Bevacizumab has also been combined 
with sunitinib (Sutent®), a tyrosine kinase inhibitor, with 
the hypothesis that this combination may increase antitu­
mor efficacy by maximizing inhibition of the VEGF 
pathway. The Bevacizumab dose was kept constant 
(10 mg/kg) while the sunitinib dose was escalated starting 
at 25 mg (escalation with 12.5 mg increments). Of 13 
patients evaluated for best response, 4 had partial respon­
ses, 7 had stable disease, and 2 had PD [17].
Similarly, the combination of Bevacizumab and the 
mTOR inhibitor CCI-779 (Temsirolimus®) has been 
investigated. Patients received 25 mg/week Temsirolimus 
and 5 or 10 mg/kg Bevacizumab. In 12 evaluable patients, 
7 PR and 3 SD were observed [18]. The encouraging 
results certainly deserve further testing of these combina­
tions in phase II trials.
Monoclonal antibody G250
G250 is a mAb against CA9, a molecule which is ubiqui­
tously expressed in ccRCC [19]. CA9 expression in non- 
ccRCC has also been documented, and there, it is most 
likely a reflection of (sustained) hypoxia [20]. Clinical 
efforts with mAb G250 in RCC have focused on radio­
immunotherapy and passive immunotherapy. This mAb 
was described as a mAb recognizing an RCC-associated 
antigen, absent in normal kidney and homogeneously 
expressed in most RCC [4], most notably clear cell RCC 
[19]. In 2000, the G250 antigen molecule was identified
and shown to be CA9 [21]. The molecular characterization 
allowed transcriptional regulation studies that revealed a 
strict dependence of G250 expression on HIF-1a [22]. 
Thus, the molecular mechanism responsible for CAIX 
expression in ccRCC is similar to VEGF, namely due to 
non-functional VHL protein leading to HIF-1a accumula­
tion and gene expression.
The first clinical trials with mAbG250 were already 
performed and published before the molecular character­
ization of G250 antigen was achieved. The combined data 
from the immunohistochemical tissue distribution, animal 
experiments and ex vivo perfusion of tumor bearing kid­
neys had provided sufficient evidence to initiate a biopsy- 
based phase I protein dose escalation trial with murine 
mAbG250. The rationale of G250-directed therapy obvi­
ously differs from Bevacizumab: Bevacizumab treatment 
leads to VEGF-depletion and consequently to diminished 
neovascularization whereas G250 treatment targets RCC 
cells directly. This first mAbG250 clinical trial demon­
strated various pivotal aspects: most notably, virtually no 
uptake in other tissues resulting in excellent tumor visu­
alization, and very high tumor uptake [23].
The G250 antibody uptake that was observed was up to 
10-fold higher than any other mAb uptake in solid tumors, 
which led to the design of a phase I/II radioimmunotherapy 
(RIT) trial with murine mAbG250. RIT led to stabilization 
of disease in 17 of 33 patients, with tumor shrinkage 
observed in two patients. Transient liver toxicity was 
observed, quite likely the result of mAbG250 liver uptake, 
although there was no correlation between the amount of
I administered or hepatic absorbed radiation dose and 
the extent and nature of hepatic toxicity [24].
Because the murine G250 antibody was highly immu­
nogenic, restricting multiple injections, mAbG250 was 
chimerized. The results of the phase I protein dose esca­
lation trial with chimeric G250 (cG250) basically 
duplicated the results from the murine G250 trial: virtually 
no uptake in other tissues resulting in excellent tumor 
visualization, and very high tumor uptake. The half-life of 
the antibody was extended, as was to be expected, but, 
more importantly, the chimerized from of G250 was almost 
immunosilent [25]. Thus, multiple injections became pos­
sible. Various phase I and phase II trials have been 
performed with cG250 aimed at therapeutic intervention. 
Based on the very high uptake levels, several RIT trials 
were performed. In the first phase I trial with 131I-cG250, 
one patient showed a partial response (>9 months) [26] 
which set the stage for phase II RIT trials in metastatic 
RCC patients. RIT studies with single high dose 131I-G250, 
rapid fractionated dose 131I-G250 [27], and sequential high 
dose I-G250 [28] have resulted in only occasional 
therapeutic responses, although dosimetric analyses sug­
gest that tumor-sterilizing levels can be reached. Even two
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sequential high-dose treatments with I-G250 did not 
result in objective responses, but in stabilization of previ­
ously progressive disease in a few patients. RIT with G250 
has been accompanied by bone marrow toxicity similar to 
mAb RIT in other tumor types and considering the minimal 
benefit, I-based RIT with cG250 have been abandoned. 
Since RCC is a radiotherapy resistant tumor, possibly even 
higher radiation doses are necessary to achieve tumor- 
sterilizing levels. Current G250 RIT efforts are directed to 
177-lutetium and 90-yttrium labeled G250. It is hypothe­
sized that the use of more powerful radionuclides that are 
also better retained in the tumor cells may lead to clinical 
responses. Animal experiments have demonstrated the 
superiority of 177Lu- and 90Y-labeled G250 over 131I-G250 
[29]. Importantly, stabilization of previously progressive 
disease has been observed in almost all 177Lu-G250 treated 
patients, although the maximum tolerable 177Lu dose has 
not been achieved. Dosimetric analyses of the first patients 
treated with 177Lu-G250 suggest that indeed tumor-steril­
izing levels may be achieved. Figure 1 illustrates targeting 
of 177Lu-G250 in a patient with metastatic renal cancer.
In view of the obvious tumor-specific accumulation of 
cG250, passive immunotherapy of RCC patients has also 
been studied extensively. In vitro mAbG250 can elicit 
antibody-dependent cellular cytotoxicity (ADCC), which 
can be enhanced by low dose IL-2 [30]. Various (non­
randomized) clinical trials have now been completed with 
cG250 alone, and in combination with IL2 or interferon 
[31, 32]. Thus far, these treatments appear to lead to 
extended survival time. The apparent clinical benefit 
appears to be quite substantial with a documented median 
survival of 22 months in patients with metastatic RCC who 
have progressive disease at study entry. Nevertheless, it is 
difficult to judge the value of this treatment. Clearly, ran­
domized trials are necessary to unequivocally demonstrate 
whether passive immunotherapy with cG250 is of benefit 
for metastatic RCC patients.
The largest trial, which is currently ongoing, is the 
adjuvant ARISER trial (adjuvant Rencarex immunotherapy 
phase III trial to study efficacy in nonmetastatic renal cell 
carcinoma). In this phase III randomized, double blind, 
placebo-controlled trial, patients with ECOG performance 
status of 0 with completely resected primary clear cell RCC 
and no evidence of remaining local or distant disease, are 
treated. The study is designed to detect a significant dif­
ference between the two treatment arms with respect to 
disease-free survival; patients will be followed-up long­
term to determine overall survival statistics.
Recently, the potential utility of mAbG250 as a diag­
nostic imaging agent was investigated [33]. The excellent 
imaging capability had been noted in almost all patients, 
but this line of research was not pursued mainly because 
detection of suspect renal masses and occult metastatic
Fig. 1 Anterior (left) and posterior (right) whole body scans acquired 
7 days post-injection of patient injected with177Lu-cG250. Please 
note high uptake in both pulmonary lesions and in contralateral 
kidney lesions. Uptake in liver is due to the conjugation methodology 
and is not related to G250 antigen expression
RCC was not deemed advantageous. Additionally, treat­
ment modalities for metastasized RCC were poor, and, 
therefore, efforts focused on treatment. However, with a 
steady increase of incidentally discovered renal masses and 
new therapeutic modalities becoming available, imaging 
might become of importance to distinguish more poten­
tially malignant tumours from less aggressive variants. In 
the first prospective clinical trial with I-labeled cG250, a 
very high specificity and sensitivity to identify ccRCC in 
patients with suspect renal masses was demonstrated, a 
clear indication of the potential clinical utility. Whether
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this imaging modality can be used to follow therapy effects 
remains to be determined.
In conclusion, it is reasonable to assume that Bev- 
acizumab and G250 monoclonal antibodies either as single 
agents or in combination with other agents may become 
useful additions to the armamentarium to diagnose and 
treat (cc)RCC. Several trials evaluating the combination of 
G250 or Bevacizumab with registered RCC treatments are 
currently in progress and will further define the role of 
these mAbs in RCC.
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